.
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..the youngest adult claimant was aged 21, and the eldest aged 79. the age of the youngest children's claim was 8.2 months..
updated: may 18, 2018, 10.36 am ist
.
print.
.